1 Reactive vaccination of workplaces and schools against COVID-19

2 Benjamin Faucher¹, Rania Assab¹, Jonathan Roux², Daniel Levy-Bruhl³, Cécile Tran Kiem^{4,5},

3 Simon Cauchemez⁴, Laura Zanetti⁶, Vittoria Colizza¹, Pierre-Yves Boëlle¹, Chiara Poletto¹

4 ¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75012, France

5 ²Univ Rennes, EHESP, REPERES « Recherche en Pharmaco-Epidémiologie et Recours aux Soins » – EA 7449,

- 6 15 avenue du Professeur-Léon-Bernard, CS 74312, 35043 Rennes, France
- 7 ³Santé Publique France, Saint Maurice, France
- 8 ⁴Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université de Paris, UMR2000, CNRS, Paris,
- 9 France
- 10 ⁵Collège Doctoral, Sorbonne Université, Paris, France
- 11 ⁶Haute Autorité de Santé, Saint-Denis, France
- 12
- 13
- 14 Corresponding author: Chiara Poletto (chiara.poletto@inserm.fr)
- 15
- 16
- TC

17

18 Abstract

19 As vaccination against COVID-19 stalls in some countries, increased accessibility and more

20 adaptive approaches may be useful to keep the epidemic under control. Here, we study the

21 impact of reactive vaccination targeting schools and workplaces where cases are detected,

22 with an agent-based model accounting for COVID-19 natural history, vaccine characteristics,

23 individuals' demography and behaviour and social distancing. At an equal number of doses

24 reactive vaccination produces a higher reduction in cases compared with non-reactive

strategies, in the majority of scenarios. However, at high initial vaccination coverage or low

- 26 incidence, few people are found to vaccinate around cases, thus the reactive strategy may be
- 27 less effective than non-reactive strategies with moderate/high vaccination pace. In case of
- 28 flare-ups, reactive vaccination could hinder spread if it is implemented quickly, is supported by

29 enhanced test-trace-isolate and triggers an increased vaccine uptake. These results provide

- 30 key information to plan an adaptive vaccination deployment.
- 31
- 32
- 33

34 Introduction

35 Vaccination against SARS-CoV-2 has changed the course of the COVID-19 pandemic thanks

36 to the high effectiveness of available vaccines in preventing infection and severe forms of the 37 disease. Still, several months into the vaccination campaign vaccine uptake remains below 38 official targets in many Western countries due to logistical issues, vaccine accessibility and/or 39 hesitancy. As of Fall 2021, less than 60% of the population in the United States and Europe 40 was fully vaccinated¹. With intense virus circulation still ongoing in many regions of the world 41 due to the Delta variant and the threat posed by emerging variants, it is important to 42 investigate if vaccine use could improve with adaptive delivery. Indeed, proposing vaccination 43 to individuals who were exposed to the virus allows targeting those at higher risk of infection and, furthermore, might help overcome barriers to vaccination ^{2,3} since vaccine-hesitant 44 45 people are more likely to accept vaccination when the perceived risk of infection is higher⁴.

46 Redirecting vaccine supplies to geographic areas of highest incidence (or hotspot

47 vaccination) is already part of some European countries' plans and was implemented to

48 combat the emergence of variant Delta². But other reactive vaccination schemes are

49 possible, such as ring vaccination that targets contacts of confirmed cases or contacts of

50 those contacts, or vaccination in workplaces or schools where cases have been detected.

51 This could potentially improve vaccine impact by preventing transmission where it is active

52 and even enable the efficient management of flare-ups. For outbreaks of smallpox or Ebola

53 fever, ring vaccination has proved effective to rapidly curtail the spread of cases ^{5–8}. However,

54 the experience of these past epidemics cannot be transposed directly to COVID-19 due to the

55 many differences in the infection characteristics and epidemiological context. For example,

56 COVID-19 cases are infectious a few days before symptom onset ⁹, but generally detected a

57 few days later. This means they may have had time to infect their direct contacts, preventing

58 the effectiveness of ring vaccination to prevent secondary cases. Vaccinating an extended

59 network of contacts, as could be done with the vaccination of whole workplaces or schools,

60 would have a larger impact, especially if adopted in combination with strengthened protective

61 measures to slow down transmission, such as masks, physical distancing, and contact

62 tracing. This could be feasible in many countries, leveraging the established test-trace-isolate

63 (TTI) system that enables prompt detection of clusters of cases to inform where vaccines

64 should be deployed. Properly assessing the interest of reactive vaccination therefore requires

to consider in detail the interactions of vaccine characteristics, pace of vaccination, COVID-19

66 natural history, case detection practices and overall changes in human contact behaviour.

We therefore extend an agent-based model that has been previously described ¹⁰ to quantify the impact of a reactive vaccination strategy targeting workplaces, universities and 12+ years old in schools where cases have been detected. We compare the impact of reactive vaccination with non-reactive vaccination targeting similar settings or with mass vaccination, and test these strategies alone and in combination. We explore differences in vaccine availability and logistic constraints, and assess the influence of the dynamic of the epidemic 73 and different stages of the vaccination campaign.

74 Results

75 Mass vaccination, targeted, and reactive vaccination strategies

We extend a previously described SARS-CoV-2 transmission model ¹⁰ to simulate vaccine administration, running in parallel with other interventions - i.e. contact tracing, teleworking and social restrictions. Following similar approaches ^{11–14}, the model is stochastic and individual based. It takes as input a synthetic population reproducing demographic, socialcontact information, workplace sizes and school types (Figure 1A) of a typical medium-sized French town (117,492 inhabitants). Contacts are described as a dynamic multi-layer network ¹⁰ (Figure 1B).

83 We assume that the vaccine reduced susceptibility, quantified by the vaccine effectiveness VE_{s} , and symptomatic illness after infection, quantified by VE_{sP} ¹⁵ (Figure 1C). We consider 84 a vaccination strategy based on the Cominarty vaccine ¹⁶ which is very suitable for reactive 85 86 vaccination as it is effective, requires only three weeks between the two doses conferring 87 protection and is available in large quantities. We describe the vaccine-induced protection 88 accounting for the vaccine characteristics against the Delta variant - i.e. the dominant variant 89 at the time of writing. Real-life estimates differ, reflecting the complex interplay among the 90 timing of Delta introduction in the population, the co-circulation of other variants, waning of 91 immunity and differential impact by age. In the baseline analysis we consider vaccine 92 effectiveness levels in the middle of the range of estimates provided in a systematic review ¹⁷. We used a three-week interval between doses as in the vaccine trial. ¹⁶ For vaccine 93 94 protection, we conservatively assume that there was no protection in the 2 weeks after the 95 first inoculation, followed by intermediate protection until 2 weeks after the second dose ($VE_{S,1} = 48\%$ and $VE_{SP,1} = 53\%$, see additional details in Table S2 of the Supplementary 96 Information) and maximum protection from this date on ($VE_{s,2}=70\%$ and $VE_{sp,2}=73\%$), 5 97 98 weeks after the first dose. The maximum protection values are close to the estimates 99 obtained in a meta-analysis for Delta, all vaccines combined ¹⁸. Lower and higher vaccine 100 effectiveness are also explored.



102 Figure 1. A Distribution of workplace size and of school type for the municipality of Metz (Grand Est region, 103 France), used in the simulation study. B Schematic representation of the population structure, the reactive 104 vaccination and contact tracing. The synthetic population is represented as a dynamic multi-layer network, where 105 layers encode contacts in household, workplace, school, community and transport. In the figure, school and 106 workplace layers are collapsed and community and transport are not displayed for the sake of visualisation. Nodes 107 repeatedly appear on both the household and the workplace/school layer. The identification of an infectious 108 individual (in purple in the figure) triggers the detection and isolation of his/her contacts (nodes with orange border) 109 and the vaccination of individuals attending the same workplace/school and belonging to the same household who 110 accept to be vaccinated (green). C Compartmental model of COVID-19 transmission and vaccination. Description 111 of the compartments is reported on the Methods section. D Timeline of events following infection for a case that is 112 detected in a scenario with reactive vaccination. For panels C, D transition rate parameters and their values are 113 described in the Methods and in the Supplementary Information.

To parametrise the epidemiological context we assume 32% 19,20 of the population was fully immune to the virus due to previous infection and the reproductive ratio is R=1.6, in the range of values estimated for the Delta wave of summer 2021 1,21 . We model the baseline TTI policy after the French situation, allowing 3.6 days on average from symptoms onset to detection and 2.8 average contacts detected and isolated per index case 22 (Figure 1 D). We assume that 50% of clinical cases and 10% of subclinical cases are detected, leading to an 120 overall detection rate of ~25% 20,23 . Scenarios with enhanced TTI are described later in the

121 text.

122 We then model vaccination targeting all adults older than 12 years old with baseline vaccine uptake - set to 80% in the 12-65 years old and 90% in the over 65 years old. ²⁴ We assumed 123 124 that priority risk groups (e.g. elderlies) had already been vaccinated up to that level at the start ^{25–28}. We model three *non-reactive* vaccination strategies in the general population, 125 126 where vaccination is deployed i) randomly throughout the mass vaccination program (mass) 127 or ii) in schools sites (school location, described below) or iii) in workplaces/universities 128 (workplaces/universities) chosen at random, up to the maximum number of doses available 129 daily. In the school location vaccination, we assume vaccine sites are created in relation with 130 schools to vaccinate pupils and their household members who are above 12 years old. Then, 131 we model a *reactive vaccination* strategy, where the detection of a case thanks to TTI triggers 132 the vaccination of household members and those in the same workplace or school (Figure 133 1D). In this scenario, a delay of 2 days on average is assumed between the detection of the 134 case and starting vaccination to account for logistical issues - i.e. ~5.6 days on average from 135 the index case's symptoms onset. In the context of reactive vaccination, we test scenarios 136 with vaccine uptake set to its baseline values, and as high as 100%. The impact of each 137 strategy is evaluated based on the comparison with a reference scenario, where no 138 vaccination campaign is conducted during the course of the simulation and vaccination 139 coverage remains at its initial level.

140 In Figure 2 A, B, C we compare all strategies, assuming that vaccine uptake is the same in 141 reactive and non-reactive vaccination as reference, and initial vaccination coverage is low, i.e. 142 \sim 30% over the population - with 15% of the [12,60] group and 90% of the 60+ group already 143 vaccinated at the beginning. Similar low coverage values were registered in some countries in 144 Eastern Europe and US counties during the Fall 2021^{1,29}. For non-reactive strategies, the 145 vaccination pace is varied between 100 and 500 first doses per 100,000 inhabitants per day. 146 Vaccination pace in Western countries roughly fell within these extremes for the majority of 147 the vaccination campaign, with lower values in general reached around the beginning and the 148 end, due to delivery issues at the beginning, and difficulty in overcoming barriers to 149 vaccination at the end¹. For the reactive strategy, vaccine deployment is triggered by 150 detected cases, therefore the number of doses used and the number of places where these 151 doses are administered depends on the epidemic situation. We assume moderate/high initial 152 incidence, i.e. ~160 clinical cases weekly per 100,000 inhabitants. Panel A shows the relative 153 reduction in the attack rate after two months as a function of the number of first daily doses 154 and Panel B compares the incidence profiles under different strategies with the same number of vaccine doses. The mass, school location and workplaces/universities strategies have a 155 156 similar impact on the epidemic. They lead to a reduction between 2.7% and 3% of the attack

rate with 100 first doses per 100,000 inhabitants administered each day, and between 13%
and 15% with 500 per 100,000 inhabitants. The reactive vaccination produces a stronger
reduction in cases than the three other strategies in the 2-months period (black dots in Figure
2 A and black line in Figure 2 B). We find that 417 doses per 100,000 inhabitants each day on
average are used under the epidemic scenario considered here, yielding an attack-rate
relative reduction of 20%.

163 In panel C we consider the same parametrization as in Figure A, B and we show the number 164 of first doses in time and the number of places to vaccinate - as a proxy to the incurred 165 logistics of vaccine deployment. The number of daily inoculated doses is initially high, with almost 1200 doses per 100,000 inhabitants used in a day at the peak of vaccine demand, but 166 167 declines rapidly afterwards down to 6 doses. The number of workplaces to vaccinate follows a 168 different trend. It slowly increases to reach a peak and then declines. The breakdown in 169 Figure S3 of the Supplementary Information shows that schools and large workplaces are 170 vaccinated at the very beginning. Thus a great number of vaccines are initially deployed in 171 large settings, requiring many doses, while as the epidemic spreads it reaches a large 172 number of small settings where only a few individuals can be vaccinated.



175 Figure 2. A, D, G Relative reduction (RR) in the attack rate (AR) over the first two months for all strategies as a 176 function of the vaccination pace. RR is computed as (AR_{ref} - AR)/AR_{ref} where AR_{ref} is the AR of the reference 177 scenario, where no vaccination campaign is conducted during the course of the simulation and vaccination 178 coverage remains at its initial level. AR is computed from clinical cases. Three initial vaccination coverage are 179 investigated for adults: 15%, i.e. low vacc. cov. (A); 40%, i.e. intermediate vacc. cov. (D) and 65%, i.e. high vacc. 180 cov. (G). B, E, H Incidence of clinical cases with different vaccination strategies. The non-reactive scenarios 181 plotted are obtained with the same daily vaccination pace than for reactive vaccination. Low, intermediate and high 182 vaccination coverages are investigated for adults in panels B, E, H, respectively. C Number of daily first-dose 183 vaccinations, and number of workplaces/schools (WP/S in the plot) where vaccines are deployed for the same 184 reactive scenario as in A, B - low vacc. cov., with 15% initial vaccine coverage. For the other vaccination 185 coverages the curves are qualitatively similar (results not shown). F AR RR for different initial vaccination coverage 186 of adults. The four strategies are compared at equal numbers of vaccine doses. The size of the points is 187 proportional to the average daily vaccination pace. I: AR RR for different Vaccine effectiveness levels (VE). The 188 baseline VE values used in the other panels is compared with a worst and a best scenario. The worst scenario is 189 defined by $V E_{S,1} = 30\%$, $V E_{SP,1} = 35\%$, $V E_{S,2} = 53\%$ and $V E_{SP,2} = 60\%$, while the best scenario is defined by $V E_{S,1} = 65\%$, $V E_{SP,1} = 75\%$, $V E_{S,2} = 80\%$ and $V E_{SP,2} = 95\%$. For each VE level the four 190

- 191 strategies are compared at equal number of vaccine doses. In panel I we consider the *intermediate* vaccination
- 192 coverage i.e. 40% initial coverage among adults. In all panels we assumed the following parameters: R=1.6;
- 193 Initial immunity 32%; vaccinated at the beginning 90% for 60+; 10% of individuals are doing teleworking and 5% of
- community contacts are removed. Values are means over 2000 stochastic simulations. Error bars in panels A, D,
- 195 G, F, I are derived from the standard errors of the AR. These are smaller than the size of the dots in almost all
- 196 cases. Shaded areas in panels B, C, E, H indicate the standard errors very low in panels B, E, H.

197 In panels D, E we consider an *intermediate* vaccination coverage at the beginning (40% of the 198 [12,60] group and 90% of 60+, corresponding to ~45% of the whole population). Non-reactive 199 strategies lead to a relative reduction in the attack rate after two months close to the low initial 200 coverage case. Instead, the impact of reactive vaccination is reduced. A smaller proportion of 201 people attending workplaces/schools that are targeted by vaccination are left to vaccinate, 202 therefore less vaccines are deployed with reduced impact on the epidemic at the population 203 level (Figure 2 D). Still, with ~250 doses per 100,000 inhabitants each day used on average. 204 reactive vaccination produced a 13% reduction in the attack rate. This value is close to the 205 reduction level reached with non-reactive strategies with 400 doses per 100,000 inhabitants 206 each day. The impact of reactive vaccination becomes very small when initial vaccination 207 coverage is high. Panels G. H show a scenario where 65% of the [12.60] group and 90% of 208 60+ is vaccinated at the beginning, corresponding to ~60% of the whole population close to the coverage reached in Europe in the Fall 2021¹. Only 94 daily vaccines per 100000 209 210 inhabitants are deployed each day with a 5% reduction in the attack rate compared to the 2% 211 reduction of non-reactive strategies at equal number of doses. Non-reactive strategies with 212 vaccination pace higher or equal to 300 doses per 100,000 inhabitants each day produce a 213 higher reduction in cases (~8% or higher).

214 The effect of the initial vaccination coverage on the impact of the different strategies is 215 summarized in Figure 2 F. The relative reduction declines roughly linearly with the initial vaccination coverage. The reactive vaccination always outperforms non-reactive strategies at 216 217 equal number of doses. Still, the number of vaccinated people in the reactive vaccination 218 progressively decreases as initial vaccination coverage increases, to reach the point in which 219 the strategy is less effective compared to non-reactive strategies with not-small vaccination 220 pace. Eventually, in panel I we explore different levels of vaccine effectiveness encompassing 221 the whole range of estimates provided by real life estimates ¹⁷. We find that lower vaccine 222 effectiveness values lead to a reduced effect of vaccination as expected. The difference 223 between reactive and non-reactive strategies is also reduced.

In the Supplementary Information we analyse the comparison between reactive and nonreactive strategies with varying key parameters. In Figure S4 we assumed the baseline scenario of Figure 2 D, E, i.e. intermediate vaccination coverage at the beginning - ~45% of the whole population vaccinated. We explore alternative values of transmission, incubation period, immunity level of the population, reduction in contacts due to social distancing, time 229 needed for the vaccine to become effective, compliance to vaccination and vaccine effect on 230 the infection duration. Increase in the reproductive ratio, initial immunity and time between 231 doses reduce the impact of the reactive vaccination. An increase in compliance to 232 vaccination, instead, enhanced the impact of both reactive and non-reactive vaccination. 233 Other parameters had a more limited role on strategies' effectiveness. We then consider a 234 scenario of a flare-up of cases, as it may be caused by a new variant of concern (VOC) 235 spreading in the territory (Figure S5). The deployment of vaccines is in this case limited and 236 slow. Depending on the values of the other parameters, i.e. proportion of teleworking and time 237 from building immunity following vaccination, the reactive strategy may bring limited or no 238 benefit with respect to non-reactive strategies, when the comparison is done at equal number 239 of doses. Eventually, we test the robustness of our results according to the selected health 240 outcome, using hospitalisations, ICU admissions, ICU bed occupancy, deaths, life-years lost and quality-adjusted life-years lost, finding the same qualitative behavior. 241

242 Combined reactive and mass vaccination for managing sustained COVID-19243 spread

244 With high availability of vaccine doses, reactive vaccination could be deployed on top of mass 245 vaccination. We consider the *intermediate* vaccination coverage scenario (i.e. ~45% of the 246 whole population vaccinated) defined in the previous section and compare mass and reactive 247 vaccination simultaneously (combined strategy) with mass vaccination alone. We focus on the 248 first two months since the implementation of the vaccination strategy. At an equal number of doses 249 within the period, the combined strategy outperforms mass vaccination in reducing the attack 250 rate. For instance, the relative reduction in the attack rate would go from 10%, when ~360 251 daily doses per 100,000 inhabitants are deployed for mass vaccination, to 16%, when the

same number of doses are used for reactive and mass vaccination combined (Figure 3A).

253 We explore alternative scenarios where the number of vaccines used and places vaccinated 254 are limited due to availability and logistic constraints. We assess the effect of three 255 parameters: (i) the maximum daily number of vaccines that can be allocated towards reactive 256 vaccination (with caps going from 50 to 250 per 100,000 inhabitants, compared with unlimited 257 vaccine availability assumed in the baseline scenario), (ii) the time from the detection of a 258 case and the vaccine deployment (set to 2 days in the baseline scenario, and here explored 259 between 1 and 4 days), and (iii) the number of detected cases that triggers vaccination in a 260 place (from 2 to 5 cases, vs. the baseline value of 1). The number of first-dose vaccinations in 261 time under the different caps is plotted in Figure 3 B. A small cap on the number of doses 262 limits the impact of the reactive strategy. Figure 3 C shows that the attack rate relative 263 reduction drops from 16% to 6% if only a maximum of 50 first doses per 100,000 inhabitants 264 daily can be used in reactive vaccination, reaching the levels of mass vaccination only.

- 265 Doubling the time required to start reactive vaccination, from 2 days to 4 days, has a limited
- 266 effect on the reduction of the AR (relative reduction reduced from 16% to 15%, Figure 3D).
- 267 Increasing the number of detected cases used to trigger vaccination to 2 (respectively 5)
- reduces the relative reduction to 11% (respectively 6%) (Figure 3E).
- 269 We so far assumed that vaccine uptake is the same in mass and reactive vaccination. This
- 270 assumption is likely conservative, in that individuals may be more inclined to accept
- 271 vaccination when this is proposed in the context of reactive vaccination due to the higher
- 272 perceived benefit of vaccination. In Figure 3F we consider a scenario where vaccine uptake
- 273 with reactive vaccination climbs to 100%. Attack rate relative reduction increases in this case
- from 16% to 22%, with a demand of ~480 daily doses per 100,000 inhabitants on average.



275 276

277 Figure 3. A Relative reduction (RR) in the attack rate (AR) over the first two months for the combined strategy 278 (mass / reactive) and the mass strategy with the same number of first-dose vaccinations as in the combined 279 strategy during the period. RR is computed with respect to the reference scenario with initial vaccination only, as in 280 Figure 2. Combined strategy is obtained by running in parallel the mass strategy - from 50 to 250 daily vaccination 281 rate per 100,000 inhabitants - and the reactive strategy. Number of doses displayed in the x-axis of the figure is 282 the total number of doses used by the combined strategy daily. Corresponding incidence curves are reported in 283 Figure S7 of the Supplementary Information. B Number of first-dose vaccinations deployed each day for the 284 combined strategy with different daily vaccines' capacity limits. C, D, E AR RR for the combined strategy as a 285 function of the average daily number of first-dose vaccinations in the two-month period. Symbols of different 286 colours indicate: (C) different values of daily vaccines' capacity limit; (D) different time from case detection to 287 vaccine deployment; (E) different threshold size for the cluster to trigger vaccination. In panel C and E the curve 288 corresponding to mass vaccination only is also plotted for comparison. F Comparison between 100% and baseline 289 vaccination uptake in case of reactive vaccination. In all cases we assumed the following parameters: R=1.6; Initial

- immunity 32%; vaccinated at the beginning 90% and 40% for 60+ and <60, respectively; 10% of individuals are
- 291 doing teleworking and 5% of community contacts are removed. Values are means over 2000 stochastic
- simulations, error bars are derived from the standard errors of the AR. In panel B only the standard error of the
- 293 unlimited case is shown, this indicated by the shaded area.

294 Combined reactive and mass vaccination for managing a COVID-19 flare-up

295 We have previously said that in a scenario of flare-up of cases reactive vaccination would

- bring limited benefit compared to other strategies (Figure S5 of the Supplementary
- 297 Information). Here we analyse this scenario more in depth, assuming that reactive vaccination
- is combined with mass vaccination, but triggers an increase in vaccine uptake and is
- associated with enhanced TTI, as may be the case in a realistic scenario of alert due to initial
- 300 VOC detection.
- 301 We assume mass vaccination with 150 first doses per day per 100,000 inhabitants is
- 302 underway from the start, with *intermediate* vaccination coverage at the beginning (i.e. ~45%
- 303 of the whole population vaccinated). We assume baseline TTI is in place prior to cases'
- 304 introduction. To start a simulation, three infectious individuals carrying a VOC are introduced
- 305 in the population where the virus variant is not currently circulating. Upon detection of the first
- 306 case, we assume that TTI is enhanced, finding 70% of clinical cases, 30% of subclinical
- 307 cases (i.e. ~45% of all cases) and three times more contacts outside the household with
- 308 100% compliance to isolation (Table S4 of the Supplementary Information) the scenario
- 309 without TTI enhancement is also explored for comparison. As soon as the number of detected
- 310 cases reaches a predefined threshold, reactive vaccination is started on top of the mass
- 311 vaccination campaign. We assume vaccine uptake increases to 100% for reactive
- 312 vaccination but stays at its baseline value for other approaches.
- 313 In Figure 4 we compare the combined scenario with mass vaccination alone at an equal
- 314 number of doses, and we investigate starting the reactive vaccination after 1, 5 or 10 detected
- 315 cases. Panels A, B show the case of baseline transmissibility and vaccine effectiveness. With
- 316 reactive vaccination starting from the first detected case, the attack rate decreases by ~10%,
- 317 compared with the mass scenario. However, the added value of reactive vaccination
- 318 decreases if more detected cases are required to start the intervention. Without enhancement
- in TTI and increase in vaccine uptake, attack rate values are much higher and the benefit of
- 320 reactive vaccination over the mass vaccination is lower (\sim 3%).
- 321 In the Supplementary Information we consider different epidemic scenarios, testing different
- 322 values for the transmissibility and vaccine effectiveness including worst-case vaccine
- 323 effectiveness, and R as high as 1.8 -, finding similar trends. Eventually, we analysed the
- 324 impact of vaccination on the flare-up extinction. With the parameterization of Figure 4 A we
- 325 find probabilities of extinction equal to \sim 5.5% and \sim 6% with mass and combined strategies,

326 respectively. These values respectively become ~15% and ~18% in a best-case scenario with

327 a more rapid mounting of vaccine effect after the first dose, best-case vaccine effectiveness

328 and strong TTI.



330 Figure 4 A, B Average attack rate per 100000 inhabitants in the first two months for the enhanced (A) and baseline 331 (B) TTI scenario. Four vaccination strategies are compared: mass only, combined where the reactive vaccination 332 starts at the detection of 1, 5, 10 cases (Comb. cl. s.= 1, 5, 10 in the figure). For mass vaccination the number of 333 first-dose vaccinations during the period is the same as in the comb. cl. s=1 of the same scenario. In all panels we 334 assume the following parameters: R=1.6; Initial immunity 32%; 90% for 60+ year old and 40% for <60 years old 335 already vaccinated at the beginning; 10% of individuals are doing teleworking and 5% of community contacts are 336 removed. Corresponding incidence curves are reported in Figure S8 of the Supplementary Information. Error bars 337 are the standard errors from 8000 stochastic realisations.

338 Discussion

339 The rapid rise of new SARS-CoV-2 variants with increased transmissibility has made the

- 340 course of the COVID-19 pandemic unpredictable, posing a persistent public health threat that
- 341 jeopardises relaxation of NPIs and return to normal life ^{25,30–34}. More transmissible viruses call
- 342 for vaccination of a larger proportion of the population, therefore vaccination must be made
- 343 more accessible and able to adapt to a rapidly evolving epidemic situation ². In this context,
- 344 we have analysed the reactive vaccination of workplaces, universities and schools to assess
- 345 its potential role in managing the epidemic.
- 346 We presented an agent-based model that accounts for the key factors affecting the
- 347 effectiveness of reactive vaccination: disease natural history, vaccine characteristic, individual
- 348 contact behaviour, and logistic constraints. For a wide range of epidemic scenarios, the
- 349 reactive vaccination had a stronger impact on the COVID-19 epidemic compared to non-
- 350 reactive vaccination strategies (including the standard mass vaccination) at equal number of
- 351 doses used within the two months after inception. In addition, combining reactive and mass
- 352 vaccination was more effective than mass vaccination alone. For instance, in a scenario of
- 353 moderate/high incidence with ~45% vaccination coverage at the beginning we found that the

354 relative reduction in the attack rate after two months would improve from 10% to 16% with 355 ~350 daily first vaccine doses per 100000 habitants used in a combined mass/reactive 356 vaccination approach instead of mass only. However, reactive vaccination had limited or no 357 advantage with respect to non-reactive strategies under certain circumstances, as the number 358 of doses administered with the reactive vaccination depended on the number and pace of 359 occurrence and detection of COVID-19 cases. This may be the case when vaccination 360 coverage is already high at the beginning and only a few people to vaccinate are found 361 around detected cases, or in a flare-up scenario when only a few cases are detected. Non-362 reactive strategies could then be more effective as long as the pace of vaccine administration 363 is not small. Yet, in these situations, adding reactive vaccination to mass vaccination could 364 become of interest again by triggering an increase in vaccine uptake, all the more if this is combined with enhanced TTI. 365

366 Reactive vaccination has been studied for smallpox, cholera and measles, among others 5-367 ^{7,35,36}. Hotspot vaccination was found to help in cholera outbreak response by both modelling studies and outbreak investigation ^{36,37}. It may target geographic areas defined at spatial 368 369 resolution as diverse as districts within a country, or neighbourhoods within a city, according 370 to the situation. For Ebola and smallpox ring vaccination was successfully adopted to 371 accelerate epidemic containment ⁵⁻⁷. For these infections, vaccine-induced immunity mounts 372 rapidly compared to the incubation period and contacts of an index case can be found before 373 they start transmitting since pre-symptomatic and asymptomatic transmission is almost 374 absent. Ring vaccination is also likely effective when the vaccine has post-exposure effects⁸. 375 Reactive vaccination of schools and university campuses has been implemented in the past to contain outbreaks of meningitis ³⁸ and measles ^{39,40}. 376

377 For COVID-19, the use of reactive vaccination has been reported in Ontario, the UK, Germany, France, among others ^{2,41–46}. In these places, vaccines were directed to 378 379 communities, neighbourhoods or building complexes with a large number of infections or 380 presenting epidemic clusters or surge of cases due to virus variants. The goal of these 381 campaigns was to minimise the spread of the virus, but it also addressed inequalities in 382 access and increased fairness, since a surge of cases may happen where people have difficulty in isolating due to poverty and house crowding ⁴⁷. In France, reactive vaccination 383 384 was implemented to contain the emergence of variants of concerns in the municipalities of Bordeaux, Strasbourg and Brest ^{44–46}. In the municipality of Strasbourg, vaccination slots 385 386 dedicated to students were created following the identification of a Delta cluster in an art school ⁴⁴. Despite the interest in the strategy and its inclusion in the COVID-19 response 387 plans, very limited work has been done so far to quantify its effectiveness ^{48,49}. A modelling 388 389 study on ring-vaccination suggested that the strategy could be valuable if the vaccine has 390 post-exposure efficacy and a large proportion of contacts could be identified ⁴⁹. Still, post391 exposure effects of the vaccine remain currently under-investigated, ⁵⁰ and it is likely that the 392 vaccination of the first ring of contacts alone would bring little benefit, if at all. We have here 393 tested reactive vaccination of workplaces and schools, since focusing on these settings may 394 be an efficient way to easily reach an extended group of contacts. Workplaces have been 395 found to be an important setting for COVID-19 transmission, especially specific workplaces where conditions are more favourable for spreading ^{51,52}. University settings also cover a 396 397 central role in the COVID-19 transmission, due to the higher number of contacts among 398 students, particularly if sharing common spaces in residence accommodations ⁵³. Model 399 results show that reactive vaccination of these settings could have in many circumstances a 400 stronger impact than simply reinforcing vaccination as in hotspot strategies.

401 However, the effectiveness of the reactive strategy depends on the epidemic context. We 402 found that, as vaccination coverage increases, the relative advantage of reactive vaccination 403 over non-reactive strategie diminishes. For >40% vaccination coverage among adults, the 404 relative reduction of the strategy is smaller than the one produced by non-reactive vaccination 405 at a moderate/high vaccination pace, under the hypothesis of no increase in vaccine uptake in 406 the context of reactive vaccination. As discussed before, when a cluster is identified in a given 407 workplace/school the vaccine is proposed only to a few individuals not previously vaccinated 408 and compliant to vaccination, resulting in a limited deployment of vaccine and a reduced 409 impact. In addition, breakthrough infection becomes an important driver of propagation when 410 a large proportion of individuals are vaccinated, with consequently a larger proportion of 411 subclinical cases and in turn a reduced detection rate overall. This makes the detection of 412 outbreaks and consequently the reactive deployment of vaccines more difficult.

413 If initial vaccination coverage is not too high, the feasibility and advantage of the inclusion of 414 reactive vaccination imply a trade-off between epidemic intensity and logistic constraints. At a 415 moderate/high incidence level, combining reactive and mass vaccination would substantially 416 decrease the attack rate compared to mass vaccination for the same number of doses, but 417 the large initial demand in vaccines may exceed the available stockpiles. Even with large 418 enough stockpiles, issues like the timely deployment of additional personnel in mobile vaccine 419 units and the need to quickly inform the population by communication campaigns must be 420 solved to guarantee the success of the campaign. We explored with the model the key 421 variables that would impact the strategy effectiveness. Delaying the deployment of vaccines 422 in workplaces/schools upon the detection of a case (from 2 to 4 days on average) would not 423 have a strong impact on its effectiveness. However, vaccines should be deployed at the 424 detection of the first case to avoid substantially limiting the impact of the strategy - e.g. the 425 relative reduction goes from 16% to 6% when workplaces/schools are vaccinated at the 426 detection of 5 cases (Figure 3E).

427 In the case of a COVID-19 flare-up the reactive strategy may bring an advantage if the

428 reactive strategy starts early, it is combined with increased TTI and it triggers an increase in 429 vaccine uptake. First, an early start of the reactive vaccination campaign since the detection 430 of the first VOC case requires that tests for the detection of variants must be carried out 431 guickly and with large coverage. Genomic surveillance has ramped up in many countries 432 since the emergence of the Alpha variant in late 2020. In France, nationwide surveys are 433 conducted every two weeks involving the full genome sequencing of randomly selected positive samples ⁵⁴. Approximately 50% of positive tests are also routinely screened for key 434 435 mutations to monitor the circulation of the main variants registered as VOC or VUI ⁵⁴. While 436 these volumes of screening may be regarded as sufficient to quickly identify the presence of 437 variants, the quick rising of large clusters of cases is possible, notably due to super spreading 438 events, becoming increasingly frequent as social restrictions relax. Second, reactive 439 vaccination must be part of a wider response plan, including notably a strong intensification of TTI ²³. Rapid and efficient TTI efficiently mitigates spread on its own, but it is also instrumental 440 441 to the success of reactive vaccination as it allows triggering vaccination in households, 442 workplaces and schools. Third, an increased level of vaccine uptake is essential for reactive 443 vaccination to be of interest. In many Western countries, upward trends in vaccine uptake 444 have been observed as the vaccination campaign unfolds, thanks to government mandates, 445 incentives by public health authorities, the communication effort and the strong evidence 446 regarding vaccine efficacy. Still vaccination coverage is highly heterogeneous and remains 447 low, e.g., in many countries of Eastern Europe and in many counties in the US^{1,29}. Besides 448 the individuals who oppose vaccination, a reactive strategy may have the potential to increase 449 acceptability of the vaccine by making it more accessible and anticipating an immediate 450 benefit against the risk of infection. An increase in vaccine uptake was indeed observed in the context of a reactive vaccination campaign during the course of a measles outbreak⁴. 451 452 Therefore reactive vaccination could be an important way to improve access to vaccination especially for the hard-to-reach population - and potentially increase acceptability, e.g. due to 453 454 risk perception.

The study is affected by several limitations. First, the synthetic population used in the study 455 accounts for the repartition of contacts across workplaces, schools, households, etc., 456 457 informed by contact surveys. However, numbers of contacts and risk of transmission could 458 vary greatly according to the kind of occupation. The synthetic population accounts for this 459 variability assuming that the average number of contacts from one workplace to another is gamma distributed ¹⁰. Still, no data were available to inform the model in this respect. Second, 460 461 we model vaccination uptake according to age only, when it is determined by several 462 sociodemographic factors. Clusters of vaccine hesitant individuals may play an important role in the dynamics and facilitate the epidemic persistence in the population, as it is described for 463 464 measles ⁵⁵. In those countries where vaccination coverage is high, heterogeneities in attitude 465 toward vaccination may have an impact. Third, the agent-based model is calibrated from

466 French socio-demographic data. The results of this study can be extended to countries with similar societal structure and contact patterns, as e.g. other developed countries ⁵⁶. Still, 467 468 COVID-19 transmission potential, level of disease-induced immunity, vaccination coverage, 469 and extent of social restrictions vary substantially from one country to another. In addition, the 470 time since vaccination campaign was started, the consequent extent of waning of immunity 471 and countries' strategies of administering the vaccine booster affect the level of protection of 472 the population already vaccinated and may alter the impact of reactive deployment of 473 vaccines among individuals not yet vaccinated. We explored a large set of parameters in the 474 Supplementary Information to provide fundamental understanding on the interplay between 475 the epidemic and the reactive vaccination dynamics that may aid the planning of the strategy 476 in case of future epidemic surges.

477 Methods

478 Synthetic population

We use a synthetic population for a French municipality based on the National Institute of 479 Statistics and Economic Studies (INSEE) censuses and French contact survey information 480 ^{10,57}. This includes the following input files: i) a setting-specific, time-varying network of daily 481 482 face-to-face contacts; ii) the maps between individuals and their age, iii) between individuals 483 and the household they belong to, iv) between individuals and their school, v) and between 484 individuals and their workplace. The synthetic population has age pyramid, household 485 composition, number of workplaces by size, and number of schools by type, reproducing 486 INSEE statistics. Daily face-to-face contacts among individuals are labelled according to the 487 setting in which they occur (either household, workplace, school, community or transport) and 488 they have assigned a daily frequency of activation, to explicitly model recurrent and sporadic 489 contacts. We consider the municipality of Metz in the Grand Est region, which has 117,492 inhabitants, 131 schools (from kindergarten to University) and 2888 workplaces (Figure 1A). 490 491 Detailed description of how the population was generated is provided in ¹⁰. Information about 492 how to access population files is provided in the Data availability section.

493 **Overview of the model**

The model is written in C/C++, and is stochastic and discrete-time. It accounts for the following components: (i) teleworking and social distancing, (ii) COVID-19 transmission, accounting for the effect of the vaccine; (iii) test-trace-isolate; (iv) vaccine deployment. Model output includes time series of incidence (clinical and subclinical cases), detailed information on infected cases (time of infection, age, vaccination status), vaccines administered according to the strategy, number of workplaces where vaccines are deployed. Different epidemic scenarios are explored and compared. In the Supplementary Information we also analyse

- 501 hospitalisation entries, deaths, ICU entries, life-year lost, quality-adjusted life-year, ICU bed
- 502 occupancy. These quantities are computed by postprocessing output files containing the
- 503 detailed information on infected cases.

504 **Teleworking and social distancing**

505 Teleworking and other social restrictions may alter the repartition of contacts across settings 506 and in turn the effectiveness of vaccination strategies ²³. We thus explicitly accounted for this 507 ingredient in the model. Specifically, to model teleworking we assume a proportion of nodes 508 are absent from work, modelled by erasing working contacts and transport contacts of these 509 nodes. To account for the reduction in social encounters due to the closure of restaurants and 510 other leisure activities we removed a proportion of contacts from the community layer. In 511 Western countries, level of restrictions varied greatly both by country and in time since 512 vaccines were first deployed at the beginning of 2021. We set the contact reduction in the community to 5% and the teleworking to 10%. These are close to the reduction values 513 reported by google mobility reports for France during Autumn 2021 ⁵⁸, and fall within the 514 515 range of European countries' estimates. Note that levels of teleworking ~10% for European countries are reported also by other sources ⁵⁹. Scenarios with different levels of contact 516 517 reduction are compared in the Supplementary Information. Telework and social distancing is 518 implemented at the beginning of the simulation and remains constant for the duration of the 519 simulation. Importantly, the reproductive ratio is set to the desired value, independently by the 520 level of contact reduction, as described in the Supplementary Information.

521 COVID-19 transmission model

Transmission model is an extension of the model in ¹⁰ (see Figure 1D). This accounts for 522 heterogeneous susceptibility and severity across age groups ^{60,61}, the presence of an exposed 523 and a pre-symptomatic stage⁹, and two different levels of infection outcome - subclinical, 524 525 corresponding to asymptomatic infection and paucisymptomatic, and clinical, corresponding to moderate to critical infection ^{60,62}. Precisely, susceptible individuals, if in contact with 526 infectious ones, may get infected and enter the exposed compartment (E). After an average 527 latency period e^{-1} they become infectious, developing a subclinical infection (I_{sc}) with age-528 dependent probability p_{sc}^{A} and a clinical infection (I_{c}) otherwise. From E, before entering either 529 I_{sc} or I_{c} , individuals enter first a prodromal phase (either $I_{p,sc}$ or $I_{p,c}$), that lasts on average 530 $\mu_{\scriptscriptstyle p}^{^{-1}}$ days. Compared to $I_{_{p,c}}$ and $I_{_c}$ individuals, individuals in the $I_{_{p,sc}}$ and $I_{_{sc}}$ compartments 531 have reduced transmissibility rescaled by a factor β_1 . With rate μ infected individuals become 532 recovered. Age-dependent susceptibility and age-dependant probability of clinical symptoms 533 534 are parametrised from ⁶⁰. In addition, transmission depends on setting as in ¹⁰. We assume that the time spent in the E, $I_{p,sc}$ and $I_{p,c}$, is Erlang distributed with shape 2, and rate 2 ϵ for 535

536 *E*, and $2\mu_p$ for $I_{p,sc}$ and $I_{p,c}$. Time spent in I_{sc} and I_c is exponentially distributed. Parameters 537 are summarised in Table S1 of the Supplementary Information.

538 We model vaccination with a leaky vaccine, partially reducing both the risk of infection (i.e. reduction in susceptibility, $V E_s$) and infection-confirmed symptomatic illness ($V E_{sp}$)¹⁵. Level 539 of protection increases progressively after the inoculation of the first dose. In our model we 540 541 did not explicitly account for the two-dose administration, but we accounted for two levels of 542 protection - e.g. a first one approximately in between of the two doses and a second one after 543 the second dose. Vaccine efficacy was zero immediately after inoculation, mounting then to an intermediate level ($V E_{S,1}$ and $V E_{SP,1}$) and a maximum level later ($V E_{S,2}$ and $V E_{SP,2}$). 544 545 This is represented through the compartmental model in Figure 1C. Upon administering the first dose, S individuals become, $S^{V,0}$, i.e. individuals that are vaccinated, but have no vaccine 546 protection. If they do not become infected, they enter the stage $S^{V,1}$, where they are partially 547 protected, then stage $S^{V,2}$ where vaccine protection is maximum. Time spent in $S^{V,0}$ and $S^{V,1}$ 548 is Erlang distributed with shape 2 and rate $2/\tau_0$ and $2/\tau_1$ for $S^{V,0}$ and $S^{V,1}$, respectively. $S^{V,1}$ 549 and $S^{V,2}$ individuals have reduced probability of getting infected by a factor $r_{s,1} = (1 - V E_{s,1})$ 550 and $r_{S,2} = (1 - V E_{S,2})$, respectively. In case of infection, $S^{V,2}$ individuals progress first to 551 exposed vaccinated (E^{V}), then to either preclinical or pre-subclinical vaccinated ($I_{p,c}^{V}$ or $I_{p,sc}^{V}$) 552 that are followed by clinical and subclinical vaccinated respectively (I_c^V or I_{sc}^V). Probability of 553 becoming $I_{n,c}^{V}$ from E^{V} is reduced of a factor $r_{c,2} = (1 - V E_{SP,2})(1 - V E_{S,2})^{-1}$. For the $S^{V,1}$ 554 individuals that get infected we assume a polarised vaccine effect, i.e. they can enter either in 555 E^{V} , with probability p_{V} , or in E (Figure 1D). The value of p_{V} can be set based on $VE_{SP,1}$ 556 through the relation $(1 - VE_{SP,1}) = (1 - VE_{S,1})(p_V r_{c,2} + (1 - p_V))$. We assume no reduction in 557 558 infectiousness for vaccinated individuals. However, we accounted for a 25% reduction in the duration of the infectious period as reported in ^{63,64}. 559

560 Under the assumption that no serological/virological/antigenic test is done before vaccine 561 administration, the vaccine is administered to all individuals, except for clinical cases who 562 show clear signs of the disease or individuals that were detected as infected by the TTI in 563 place. In our model a vaccine administered to infected or recovered individuals has no effect.

In the baseline scenario we parametrise $V E_{SP,1}$, $V E_{SP,2}$, $V E_{S,1}$ and $V E_{S,2}$ by taking values in the middle of estimates reported in the systematic review by Higdon and collaborators ¹⁷ for the Comirnaty vaccine and the Delta variant ⁶⁵. Chosen values of $V E_{SP,2}$, and $V E_{S,2}$ are also comparable with the effectiveness estimates reported in a meta-analysis for the Delta variant, complete vaccination, all vaccines combined ¹⁸. We also test values on the upper and lower

- 569 extremes of the range of estimates of ¹⁷. Parameters are listed in Table S2 of the
- 570 Supplementary Information.

571 Test-trace-isolate

- 572 We model a baseline TTI accounting for case detection, household isolation and manual
- 573 contact tracing. Fifty percent of individuals with clinical symptoms were assumed to get tested
- 574 and to isolate if positive. We assume an exponentially distributed delay from symptoms onset
- to case detection and its isolation with 3.6 days on average. Once a case is detected, his/her
- box household members isolate with probability $p_{ct,HH}$, while other contacts isolate with
- 577 probabilities $p_{ct,A}$ and $p_{ct,Oth}$, for acquaintances and sporadic contacts, respectively. In addition
- 578 to the detection of clinical cases, we assume that a proportion of subclinical cases were also
- 579 identified (10%). Isolated individuals resume normal daily life after 10 days unless they still
- 580 have clinical symptoms after the time has passed. They may, however, decide to drop out
- 581 from isolation each day with a probability of 13% if they do not have symptoms ⁶⁶.
- In the scenario of virus re-introduction we consider enhanced TTI, corresponding to a
- 583 situation of case investigation, screening campaign and sensibilisation (prompting higher
- 584 compliance to isolation). We assume a higher detection of clinical and subclinical cases (70%
- and 30%, respectively), perfect compliance to isolation by the index case and household
- 586 members and a three-fold increase in contacts identified outside the household.
- 587 Step-by-step description of contact tracing is provided in the Supplementary Information.
- 588 Parameters for baseline TTI are provided in Table S3, while parameters for enhanced TTI are 589 provided in Table S4.

590 Vaccination strategies

- 591 A vaccine opinion (willingness or not to vaccinate) is stochastically assigned to each
- 592 individual at the beginning of the simulation depending on age (below/above 65 years old).
- 593 Opinion does not change during the simulation. In some scenarios we assume that all
- 594 individuals are willing to accept the vaccine in case of reactive vaccination, while maintaining
- 595 the opinion originally assigned to them when the vaccine is proposed in the context of non-
- reactive vaccination. Only individuals above a threshold age, $a_{th, V} = 12$ years old, are
- 597 vaccinated. We assume that a certain fraction of individuals are vaccinated at the beginning
- of the simulation according to the age group ([12,60], 60+). We compare the following
- 599 vaccination strategies:
- 600 *Mass*: V_{daily} randomly selected individuals are vaccinated each day until a V_{tot} limit is 601 reached.

- 602 Workplaces/universities: Random workplaces/universities are selected each day. All
- 603 individuals belonging to the place, willing to be vaccinated, and not isolated at home that day 604 are vaccinated. Individuals in workplaces/universities are vaccinated each day until the daily 605 limit, V_{daily} is reached. No more than V_{tot} individuals are vaccinated during the course of the 606 simulation. We assume that only workplaces with iith=20i employees or larger implement 607 vaccination.

608 *School location*: Random schools, other than universities, are selected each day and a 609 vaccination campaign is conducted in the places open to all household members of school 610 students. All household members willing to be vaccinated, above the threshold age and not 611 isolated at home that day are vaccinated. No more than V_{daily} individuals are vaccinated each

- 612 day and no more than V_{tot} individuals are vaccinated during the course of the simulation.
- 613 *Reactive*: When a case is detected, vaccination is done in her/his household with rate r_V^{\Box} .
- 614 When a cluster i.e. at least n_{cl} cases detected within a time window of length T_{cl} is
- 615 detected in a workplace/school, vaccination is done in that place with rate r_V^{\Box} . In the baseline
- 616 scenario, we assume vaccination in workplace/school to be triggered by one single infected
- 617 individual ($n_{cl}=1$). In both household and workplace/school, all individuals belonging to the
- 618 place above the threshold age and willing to be vaccinated are vaccinated. Individuals that
- 619 were already detected and isolated at home are not vaccinated. No more than V_{daily}
- 620 individuals are vaccinated each day and no more than V_{tot} individuals are vaccinated during
- 621 the course of the simulation. In the baseline scenario these quantities are unlimited, i.e. all
- 622 individuals to be vaccinated in the context of reactive vaccination are vaccinated.
- 623 Parameters and their values are summarised in Table S5 of the Supplementary Information.

624 Data availability

625 The synthetic population used in the analysis is available on github ⁶⁷.

626 Code availability

627 We provide all C/C++ code files of the model on github 67 .

628 References

- 1. Ritchie, H. et al. Coronavirus Pandemic (COVID-19). Our World in Data (2020).
- 630 2. Overview of the implementation of COVID-19 vaccination strategies and deployment plans
- 631 in the EU/EEA. *European Centre for Disease Prevention and Control*
- 632 https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-

- 633 vaccination-strategies-and-deployment-plans (2021).
- 634 3. To vaccinate more Americans, lean into outbreaks. STAT
- https://www.statnews.com/2021/08/19/lean-into-outbreaks-to-vaccinate-more-americans/(2021).
- 4. Le Menach, A. et al. Increased measles-mumps-rubella (MMR) vaccine uptake in the
- 638 context of a targeted immunisation campaign during a measles outbreak in a vaccine-
- reluctant community in England. *Vaccine* **32**, 1147–1152 (2014).
- 5. Merler, S. et al. Containing Ebola at the Source with Ring Vaccination. PLOS Neglected
- 641 *Tropical Diseases* **10**, e0005093 (2016).
- 642 6. Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine
- 643 expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination
- 644 cluster-randomised trial. *Lancet* (2015) doi:10.1016/S0140-6736(15)61117-5.
- 645 7. Geddes, A. M. The history of smallpox. *Clinics in Dermatology* 24, 152–157 (2006).
- 646 8. Gallagher, T. & Lipsitch, M. Postexposure Effects of Vaccines on Infectious Diseases.
- 647 *Epidemiologic Reviews* **41**, 13–27 (2019).
- 648 9. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature*
- 649 *Medicine* 1–4 (2020) doi:10.1038/s41591-020-0869-5.
- 650 10. López, J. A. M. et al. Anatomy of digital contact tracing: Role of age, transmission
- 651 setting, adoption and case detection. *Science Advances* eabd8750 (2021)
- 652 doi:10.1126/sciadv.abd8750.
- 653 11. Ajelli, M. et al. Comparing large-scale computational approaches to epidemic
- 654 modeling: Agent-based versus structured metapopulation models. *BMC Infectious*
- 655 *Diseases* **10**, 190 (2010).
- 656 12. Chao, D. L., Halloran, M. E., Obenchain, V. J. & Jr, I. M. L. FluTE, a Publicly Available
- 657 Stochastic Influenza Epidemic Simulation Model. *PLOS Comput Biol* **6**, e1000656 (2010).
- 13. Willem, L., Verelst, F., Bilcke, J., Hens, N. & Beutels, P. Lessons from a decade of
- 659 individual-based models for infectious disease transmission: a systematic review (2006-
- 660 2015). BMC Infectious Diseases **17**, 612 (2017).
- 661 14. Liu, Q.-H. et al. Measurability of the epidemic reproduction number in data-driven

- 662 contact networks. *PNAS* **115**, 12680–12685 (2018).
- Basta, N. E., Halloran, M. E., Matrajt, L. & Longini, I. M. Estimating influenza vaccine
 efficacy from challenge and community-based study data. *Am J Epidemiol* 168, 1343–
 1352 (2008).
- 666 16. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

667 New England Journal of Medicine **383**, 2603–2615 (2020).

- 668 17. Higdon, M. M. et al. A systematic review of COVID-19 vaccine efficacy and
- 669 effectiveness against SARS-CoV-2 infection and disease. 2021.09.17.21263549
- 670 https://www.medrxiv.org/content/10.1101/2021.09.17.21263549v1 (2021)
- 671 doi:10.1101/2021.09.17.21263549.
- 18. Harder, T. *et al.* Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection
- 673 with the Delta (B.1.617.2) variant: second interim results of a living systematic review and
- 674 meta-analysis, 1 January to 25 August 2021. *Eurosurveillance* **26**, 2100920 (2021).
- 675 19. Proportion de la population infectée par SARS-CoV-2. https://modelisation-
- 676 covid19.pasteur.fr/realtime-analysis/infected-population/.
- 677 20. Hozé, N. et al. Monitoring the proportion of the population infected by SARS-CoV-2
- using age-stratified hospitalisation and serological data: a modelling study. *The Lancet*
- 679 *Public Health* **6**, e408–e415 (2021).
- 680 21. Krymova, E. *et al.* Trend estimation and short-term forecasting of COVID-19 cases
- 681 and deaths worldwide. *arXiv:2106.10203 [stat]* (2021).
- 682 22. SPF. COVID-19 : point épidémiologique du 6 mai 2021.
- 683 https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-
- 684 respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-
- 685 epidemiologique-du-6-mai-2021.
- 686 23. Pullano, G. et al. Underdetection of COVID-19 cases in France threatens epidemic
- 687 control. *Nature* 1–9 (2020) doi:10.1038/s41586-020-03095-6.
- 688 24. COVID-19: Willingness to be vaccinated | YouGov.
- 689 https://yougov.co.uk/topics/international/articles-reports/2021/01/12/covid-19-willingness-
- 690 be-vaccinated.

- 691 25. Kiem, C. T. *et al.* Short and medium-term challenges for COVID-19 vaccination: from
- 692 prioritisation to the relaxation of measures. (2021).
- Bubar, K. M. *et al.* Model-informed COVID-19 vaccine prioritization strategies by age
 and serostatus. *Science* (2021) doi:10.1126/science.abe6959.
- 695 27. Matrajt, L., Eaton, J., Leung, T. & Brown, E. R. Vaccine optimization for COVID-19:
- 696 Who to vaccinate first? *Science Advances* **7**, eabf1374 (2020).
- 697 28. Lu, D. et al. Data-driven estimate of SARS-CoV-2 herd immunity threshold in
- 698 populations with individual contact pattern variations. *medRxiv* 2021.03.19.21253974
- 699 (2021) doi:10.1101/2021.03.19.21253974.
- 700 29. US COVID-19 Vaccination Tracking. http://www.vaccinetracking.us/.
- 30. Huang, B. et al. Integrated vaccination and physical distancing interventions to
- prevent future COVID-19 waves in Chinese cities. *Nat Hum Behav* **5**, 695–705 (2021).
- 703 31. Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L. & Keeling, M. J. Vaccination and
- non-pharmaceutical interventions for COVID-19: a mathematical modelling study. *The Lancet Infectious Diseases* 21, 793–802 (2021).
- 706 32. Yang, J. et al. Despite vaccination, China needs non-pharmaceutical interventions to
- prevent widespread outbreaks of COVID-19 in 2021. *Nat Hum Behav* 1–12 (2021)
- 708 doi:10.1038/s41562-021-01155-z.
- 33. Gozzi, N., Bajardi, P. & Perra, N. The importance of non-pharmaceutical interventions
- 710 during the COVID-19 vaccine rollout. *medRxiv* 2021.01.09.21249480 (2021)
- 711 doi:10.1101/2021.01.09.21249480.
- 712 34. Bosetti, P. et al. Epidemiology and control of SARS-CoV-2 epidemics in partially
- vaccinated populations: a modeling study applied to France. (2021).
- 714 35. Grais, R. F. et al. Time is of the essence: exploring a measles outbreak response
- vaccination in Niamey, Niger. *Journal of The Royal Society Interface* (2007)
- 716 doi:10.1098/rsif.2007.1038.
- 717 36. Finger, F. et al. The potential impact of case-area targeted interventions in response
- to cholera outbreaks: A modeling study. *PLOS Medicine* **15**, e1002509 (2018).
- 719 37. Martin, S. et al. Post-licensure deployment of oral cholera vaccines: a systematic

- 720 review. Bull World Health Organ 92, 881–893 (2014).
- 721 38. Capitano, B., Dillon, K., LeDuc, A., Atkinson, B. & Burman, C. Experience
- implementing a university-based mass immunization program in response to a
- meningococcal B outbreak. *Human Vaccines & Immunotherapeutics* **15**, 717–724 (2019).
- 39. Pegorie, M. *et al.* Measles outbreak in Greater Manchester, England, October 2012 to
- September 2013: epidemiology and control. *Eurosurveillance* **19**, 20982 (2014).
- 40. Kirolos, A. *et al.* Imported case of measles in a university setting leading to an
- outbreak of measles in Edinburgh, Scotland from September to December 2016.
- 728 *Epidemiology & Infection* **146**, 741–746 (2018).
- 729 41. Ontario's COVID-19 vaccination plan. COVID-19 (coronavirus) in Ontario
- 730 https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan.
- 731 42. Covid-19: More variant hotspots to get surge tests and jabs. BBC News (2021).
- 43. Welle (www.dw.com), D. COVID: Cologne project aims to vaccinate urban hot spots |
- 733 DW | 08.05.2021. DW.COM https://www.dw.com/en/covid-cologne-project-aims-to-
- vaccinate-urban-hot-spots/a-57472989.
- 735 44. COVID-19 : présence du variant indien dans l'Eurométropole et plan d'actions
- immédiat. http://www.grand-est.ars.sante.fr/covid-19-presence-du-variant-indien-dans-
- 737 leurometropole-et-plan-dactions-immediat.
- 738 45. COVID-19 : en Pays de Brest, la vaccination s'accélère.
- 739 http://www.bretagne.ars.sante.fr/covid-19-en-pays-de-brest-la-vaccination-saccelere.
- 740 46. Communiqué de presse Covid-19 La nécessité de se faire vacciner rapidement
- pour éviter la propagation du virus, notamment du variant delta. http://www.nouvelle-
- 742 aquitaine.ars.sante.fr/communique-de-presse-covid-19-la-necessite-de-se-faire-vacciner-
- rapidement-pour-eviter-la.
- 47. Valdano, E., Lee, J., Bansal, S., Rubrichi, S. & Colizza, V. Highlighting socio-
- economic constraints on mobility reductions during COVID-19 restrictions in France can
- inform effective and equitable pandemic response. *Journal of Travel Medicine* **28**, (2021).
- 747 48. Xu, W., Su, S. & Jiang, S. Ring vaccination of COVID-19 vaccines in medium- and
- high-risk areas of countries with low incidence of SARS-CoV-2 infection. *Clin Transl Med*

- 749 **11**, e331 (2021).
- 750 49. MacIntyre, C. R., Costantino, V. & Trent, M. Modelling of COVID-19 vaccination
- strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW,
- 752 Australia. *Vaccine* (2021) doi:10.1016/j.vaccine.2021.04.042.
- Muller, C. P. Can integrated post-exposure vaccination against SARS-COV2 mitigate
 severe disease? *The Lancet Regional Health Europe* 5, (2021).
- 755 51. Althouse, B. M. et al. Superspreading events in the transmission dynamics of SARS-
- CoV-2: Opportunities for interventions and control. *PLOS Biology* **18**, e3000897 (2020).
- 757 52. Leclerc, Q. J. et al. What settings have been linked to SARS-CoV-2 transmission
- 758 clusters? Wellcome Open Research 5, 83 (2020).
- 759 53. Christensen, H. et al. COVID-19 transmission in a university setting: a rapid review of
- 760 modelling studies. *medRxiv* 2020.09.07.20189688 (2020)
- 761 doi:10.1101/2020.09.07.20189688.
- 762 54. Coronavirus : circulation des variants du SARS-CoV-2.
- 763 https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-circulation-
- des-variants-du-sars-cov-2.
- 765 55. Metcalf, C. J. E. *et al.* Seven challenges in modeling vaccine preventable diseases.
- 766 *Epidemics* **10**, 11–15 (2015).
- 767 56. Mistry, D. *et al.* Inferring high-resolution human mixing patterns for disease modeling.
 768 *arXiv:2003.01214 [physics, q-bio]* (2020).
- 769 57. Béraud, G. et al. The French Connection: The First Large Population-Based Contact
- Survey in France Relevant for the Spread of Infectious Diseases. *PLOS ONE* **10**,
- 771 e0133203 (2015).
- 772 58. COVID-19 Community Mobility Report. COVID-19 Community Mobility Report https://
- 773 www.google.com/covid19/mobility?hl=en.
- 59. Personal measures taken to avoid COVID-19 | YouGov.
- 775 https://yougov.co.uk/topics/international/articles-reports/2020/03/17/personal-measures-
- taken-avoid-covid-19.
- 777 60. Davies, N. G. et al. Age-dependent effects in the transmission and control of COVID-

- 778 19 epidemics. *Nature Medicine* 1–7 (2020) doi:10.1038/s41591-020-0962-9.
- 779 61. Di Domenico, L., Pullano, G., Sabbatini, C. E., Boëlle, P.-Y. & Colizza, V. Modelling
- safe protocols for reopening schools during the COVID-19 pandemic in France. *Nat*
- 781 *Commun* **12**, 1073 (2021).
- 782 62. Riccardo, F. et al. Epidemiological characteristics of COVID-19 cases and estimates
- of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March
- 784 2020. *Eurosurveillance* **25**, 2000790 (2020).
- 785 63. Kissler, S. M. et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and
- 786 *unvaccinated individuals*. 2021.02.16.21251535
- 787 https://www.medrxiv.org/content/10.1101/2021.02.16.21251535v3 (2021)
- 788 doi:10.1101/2021.02.16.21251535.
- 789 64. Blanquart, F. et al. Characterisation of vaccine breakthrough infections of SARS-CoV-
- 2 Delta and Alpha variants and within-host viral load dynamics in the community, France,
- June to July 2021. *Eurosurveillance* **26**, 2100824 (2021).
- 792 65. Dagan, N. et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
- 793 Vaccination Setting. *New England Journal of Medicine* (2021)
- 794 doi:10.1056/NEJMoa2101765.
- 795 66. Smith, L. E. et al. Adherence to the test, trace and isolate system: results from a time
- series of 21 nationally representative surveys in the UK (the COVID-19 Rapid Survey of
- Adherence to Interventions and Responses [CORSAIR] study). *medRxiv* (2020)
- 798 doi:10.1101/2020.09.15.20191957.
- 799 67. PYB-SU. PYB-SU/ReactiveVaccination.
- 800 https://github.com/PYB-SU/ReactiveVaccination (2021).

801 Acknowledgements

- 802 We acknowledge financial support from Haute Autorité de Santé; the ANR and Fondation de
- 803 France through the project NoCOV (00105995); the Municipality of Paris
- 804 (https://www.paris.fr/) through the programme Emergence(s); EU H2020 grants MOOD
- 805 (H2020-874850), and RECOVER (H2020-101003589); the ANRS through the project

- 806 EMERGEN (ANRS0151); the ANR through the project SPHINX (ANR-17-CE36-0008-05);
- 807 Institut des Sciences du Calcul et de la Donnée.Supplementary Information

810 Supplementary Information

- 811 Additional Methods
- 812

813 COVID-19 transmission model

814 We provide here in the following the parameter values for transmission and infection natural 815 history (Table S1), and the effect of vaccination (Table S2). For a detailed explanation of the 816 transmission model without vaccination we refer to ¹. Incubation period *IP* and length of the 817 pre-symptomatic phase μ_p are specific for the Delta variant. In particular, μ_p is prametrised 818 based on the proportion of pre-symptomatic transmission estimated in ².

819

820 Table S1. Transmission parameters and their baseline values.

Parameter	Description	Baseline value (other explored values)	Source
IP	Incubation period	5.8 days (5.1 days, 6.3 days)	² (^{3,4})
μ_p	Rate of developing symptoms for pre- symptomatic individuals	(2.1 days) ⁻¹	Computed to recover 74% of pre-symptomatic transmission as estimated in ²
E	Rate of becoming infectious for exposed individuals	(3.7 days) ⁻¹	$IP - \mu_p^{-1}$
μ	Recovery rate	(7 days) ⁻¹	5
$eta_{\scriptscriptstyle I}$	transmissibility rescaling according to the infectious stage	0.51 for $I_{p,sc}$, I_{sc} 1 for $I_{p,c}$, I_{c}	6
ω _s	Transmission risk by setting (network layer)	1 for <i>H</i> layer 0.3 for <i>C</i> layer	1
		0.5 otherwise	

821

822 Table S2. Vaccine effectiveness parameters and their baseline values.

Parameter D	Description	Baseline value	Source
Parameter D	Description	Baseline value	Source

		(other explored values)	
r _{5,1}	reduction in susceptibility in the partial-protection stage	0.52 (0.35, 0.7)	from $V E_{S,1} = 48$ %, in the middle of the range of estimates after one dose in ⁷ (from 30%, 65%, worst and best estimates from ⁷ , respectively)
τ ₀	Average duration of the no- protection stage after first-dose inoculation	(2 weeks) ⁻¹ ((1 week) ⁻¹)	
r _{s,2}	reduction in susceptibility in the maximum-protection stage	0.3 (0.2, 0.47)	from $V E_{S,2} = 70$ %, in the middle of the range of estimates after two doses in ⁷ (from 53%, 80%, worst and best estimates from ⁷ , respectively)
r _{c,2}	reduction in the probability of developing clinical symptoms in the maximum-protection stage	0.9 (0.4, 0.95)	from $V E_{SP,2} = 73$ %, in the middle of the range of estimates after two doses in ⁷ (from 60%, 95%, worst and best estimates from ⁷ , respectively)
τ ₁	Average duration of the intermediate-protection stage	(3 weeks) ⁻¹ ((4 week) ⁻¹ , (8 week) ⁻¹)	8
p_V	Probability of transition between $S^{V,1}$ and E^V	0.97 (0.65, 0.82)	Computed from the parameters above and assuming $V E_{SP,1} = 53\%$, in the middle of the range of estimates after one dose in ⁷ (from 35%, 75%, worst and best estimates from ⁷ , respectively) (*)
r _I	Reduction in infection duration	25% (0)	9

^{823 (*)} Mid range estimate in ⁷, $V E_{SP} = 55$ %, leads to a value of $p_V > 1$, thus $V E_{SP} = 53$ % is taken.

825 Test-trace-isolate

We model case detection and isolation, combined with tracing and isolation of contactsaccording to the following rules:

- 828 As an individual shows clinical symptoms, s/he is detected with probability $p_{d,c}$. If
- detected, case confirmation and isolation occur with rate r_d upon symptoms onset.
- 830 Subclinical individuals are also detected with probability $p_{d,sc}$, and rate r_d .

- The index case's household contacts are isolated, with probability $p_{ct, HH}$, the same time the index case is detected and isolated. We assume that these contacts are tested at the time of isolation and among those all subclinical, clinical, pre-subclinical, and pre-clinical cases are detected (testing sensitivity 100%).
- Once the index case is detected, contacts of the index case occurring outside the
- household are traced and isolated with an average delay r_{ct}^{-1} . We define an acquaintance
- as a contact occurring frequently, i.e. with a frequency of activation higher than f_a . We
- assume that an acquaintance is detected and isolated with a probability $p_{ct,A}$, while other
- 839 contacts (i.e. sporadic contacts) are detected and isolated with probability $p_{ct,sp}$, with
- 840 $p_{ct,A} > p_{ct,sp}$. We assume that traced contacts are tested at the time of isolation and among 841 those all subclinical, clinical, pre-subclinical, and pre-clinical cases are detected (testing 842 sensitivity 100%).
- Only contacts (among contacts occurring both in household and outside) occurring within a window of *D* days before index case detection are considered for contact tracing.
- The index-case and the contacts are isolated for a duration d_I (for all infected compartments) and d_i (for susceptible and recovered compartments). Contacts with no clinical symptoms have a daily probability p_{drop} to drop out from isolation.
- For both the case and the contacts, isolation is implemented by assuming no contacts
 outside the household and transmission risk per contact within a household reduced by a
 factor *ι*.
- Parameter values are reported in Table S3 and Table S4 for baseline and enhanced TTI,respectively.
- 853

Table S3. Model for test, trace, isolation. Parameters and their values for the baseline case.

Parameter	Description	Value	Source
$p_{d,c}$	Probability that a clinical case is detected	0.5	
$p_{d,sc}$	Probability that a subclinical case is detected	0.1	
r _d	For detected cases, rate of detection, confirmation and beginning of isolation	0.28 = (3.6 days) ⁻¹	Average time from onset to testing is 2.6 days ¹⁰ . We assume one day to have the

D	Length of the period preceding index- case confirmation, used to define a contact	6 days (*)	\simeq 2 days + $i r_d^{-1}$ (a person is considered to be contact if s/he entered in contact with the index case during a window of 2 days preceding symptoms onset)
<i>р</i> _{сt, НН}	Probability that household contacts of an index case are identified and decide to isolate	0.7	
P _{ct,A}	Probability that acquittances of an index case are identified and decide to isolate	0.08	Calibrated to get \simeq 2.8 contacts per index case on average (assumed $p_{ct,Oth} = p_{ct,A}/10$
$p_{\scriptscriptstyle ct,Oth}$	Probability that sporadic contacts of an index case are identified and decide to isolate	0.008	Calibrated to get \simeq 2.8 contacts per index case on average (assumed $p_{ct,Oth} = p_{ct,A}/10$ i
r _{ct}	Rate of detection and isolation of contacts outside household	0.9 = (1.1 days) ⁻¹	
f _a	Threshold frequency to define a contact as an acquaintance	1/7 days	
p_{do}	Probability to drop out from isolation for individuals that are not clinical	0.13	11
ι	Reduction in household transmission during isolation	0.5	
d_i, d_I	Duration of isolation for an individual that is not infectious, duration of isolation for an individual that is infectious	10 days, 10 days	12

Table S4. Model for case test, trace, isolation. Parameters and their values for the case of enhanced TTI. Only values different from the baseline case are reported.

Parameter	Description	Baseline value (other explored values)
$p_{d,c}$	Probability that a clinical case is detected	0.7 (1)
$p_{d,sc}$	Probability that a subclinical case is detected	0.3 (0.5)
r _d	For detected cases, rate of detection, confirmation and beginning of isolation	0.9 = (1.1 days) ⁻¹

$p_{ct,HH}$	Probability that household contacts of an index case are identified and decide to isolate	1
$p_{ct,A}$	Probability that acquittances of an index case are identified and decide to isolate	0.24
$p_{\scriptscriptstyle ct,Oth}$	Probability that sporadic conatcts of an index case are identified and decide to isolate	0.024
p_{do}	Probability to drop out from isolation for individuals that are not clinical	0

859 Vaccination strategies

860 We provide here in the following the parameters values for the vaccination strategies detailed

861 in the Methods section of the main paper.

862

863 Table S5. Vaccine administering. Parameters and their baseline values.

Parameter	Description	Baseline values (other explored values)
a _{th,V}	Minimum age for vaccination	12 years
P_V^a	Probability an individual is willing to	90% for 65+
	vaccinate	80% for <65 (60%, 100%)
n _{cl}	For reactive vaccination, cluster size for	1 (2, 3, 4, 5)
	triggering reactive vaccination in a workplace	
	For reactive vaccination, time window	7 days
	for cluster definition	
$(r_{v})^{-1}$	For reactive vaccination, delay of	2 days (1 day, 4 days)
(•)	implementation of the vaccination	
	campaign once the cluster is identified	
	(for workplaces/schools) and a case is	
	identified (for households)	
V	Maximum number of people vaccinated	Unlimited
• 101	during one simulation	
V	Maximum number of people vaccinated	[50, 500] per 100,000 inhabitants per day for Mass
v _{day}	each day	workplaces/universities_school location
	cach day	workplaces/universities, school location
		Unlimited for reactive ([50, 250] per 100,000

		inhabitants per day)
iithi	For WP/U, minimum size of a workplace that implement vaccination	20
n _{RV}	For reactive vaccination, cluster size for starting the reactive vaccination	1, 5, 10
	Initial vaccination coverage	90% for 65+
		40% for <65 (15%, 25%, 35%, 45%, 55%, 65%, 75%)

865 Details on the epidemic simulations

- 866 A schematic representation of the main program and of the simulation code and of the
- 867 algorithm used for a single stochastic realisation are shown in Figure S1 and S2, respectively.
- 868 Simulations are discrete-time and stochastic. At each time step, corresponding to one day,
- 869 three processes occur (Figure S2):
- 870 *Vaccination Step:* vaccines are administered according to the strategy or the strategies'871 combination.
- 872 *Testing Step*: cases are detected and isolated; contacts (within and outside household) are
- 873 identified and isolated; isolated individuals get out from isolation.
- 874 Transmission Step: infectious status of nodes is updated. This includes transmission,
- 875 recovery and transition through the different stages of the infection (e.g. from exposed to pre-
- 876 symptomatic, from pre-symptomatic to symptomatic).











883 A single-run simulation is executed with no modelled intervention, until the desired immunity 884 level is reached. This guarantees that immune individuals are realistically clustered on the 885 network. We added some noise, by reshuffling the immune/susceptible status of 30% of the 886 nodes to account for travelling, infection reintroduction from other locations and large 887 gathering with consequent super-spreading not accounted for by the model. In Figure 2 and 3 888 of the main paper, all processes (transmission, TTI, vaccination) are simulated from the 889 beginning of the simulation. In the scenario with virus re-introduction (Figure 4), TTI and mass 890 vaccination are modelled from the beginning. TTI is enhanced from the detection of the first

891 case. Reactive vaccination starts after the detection of the first n_{RV} cases, with n_{RV} = 1,5,10

892 explored.

- 893 We vary COVID-19 transmission potential by tuning the daily transmission rate per contact β .
- 894 The reproductive number R is computed numerically as the average number of infections
- 895 each infected individual generates throughout its infectious period at the beginning of the
- simulation. We tune β to have the desired *R* value (1.6 for the analysis in the main text) for
- the reference scenario i.e. with only vaccination at the start. We then compare different
- 898 vaccination strategies at the same value of transmissibility β .
- 899 To calibrate the duration of the pre-symptomatic stage from 2 (value reported in Table S1) we
- 900 generated an output file containing the list of all transmission events with the infection status
- 901 of the infector. The proportion of pre-symptomatic transmission was computed as the fraction
- 902 of transmission events with infector in the compartment $I_{p,sc}$ or $I_{p,c}$ over all infection events.

903

904 Additional Results

905 Comparison between reactive and non-reactive vaccination strategies

906 Vaccinated settings

- 907 We provide here a detailed analysis of the time evolution of the number of settings where
- 908 vaccines are deployed in the context of reactive vaccination.
- 909



Figure S3. A, B Daily number of workplaces (A) and schools (B) where vaccines are deployed in the context of
 reactive vaccination. C Size of workplaces/Schools where vaccines are deployed as a function of time. Values
 are means over 2000 stochastic simulations. Shaded areas indicate the standard errors.

916 Sensitivity analysis

917 We compare here reactive vaccination with non-reactive vaccination strategies under a918 variety of epidemic scenarios.

919 In Figure S4 we compare all strategie at equal number of doses over the two month period, 920 exploring the impact of the following parameters: reproductive ratio, immunity level of the 921 population, repartition of contacts across settings due to social distancing, incubation period, 922 effect of the vaccine in the infection duration, vaccine uptake, and time between doses. 923 Except when otherwise indicated, parameters are the ones of Figure 2 D, E of the main 924 paper, i.e. intermediate vaccination coverage at the beginning (~45% of the whole population 925 vaccinated), moderate/high initial incidence and the vaccine uptake to be the same for all 926 strategies. Increasing the transmissibility or initial immunity reduces the impact of reactive 927 vaccination (panel A, B). In panel C we explore the impact of teleworking and reduction in 928 community contact by comparing the baseline scenario with scenarios with no or stronger 929 restrictions. Reactive vaccination becomes more effective when no restriction is in place -930 although the effect is not strong. This is likely due to the enhanced role of workplaces as a 931 setting of transmission when no teleworking is in place, thus bringing to an increased benefit 932 of reactive vaccination targeting this setting. In panel D, we analyse the impact of the choice 933 of the incubation period exploring incubation period values ranging from 5.1³ up to 6.3⁴. We 934 find that results are highly robust to the choice of the parameters, within this range. In panel E we compare different hypotheses regarding the effect of the vaccine on the infection duration, 935 936 i.e. the baseline case with the case in which the vaccine induces no reduction in the infectious duration. Also in this case, results are robust. Eventually in panel F we compare different 937 levels of vaccine uptake, assuming uptake to be the same in all strategies as in Figure 2 of 938 939 the main paper. The impact of vaccination increases with the uptake, the effect being stronger 940 for the reactive strategy. Eventually, we compare in panel G different timing for vaccine-941 induced immunity to become effective. Specifically, we consider a case in which partial 942 protection against infection mounts one week after the first dose. Assuming an incubation 943 period of ~6 days, this would be consistent with no reduction in cases observed ~2 weeks after first-dose inoculation, as reported by some real vaccine effectiveness studies ^{14,15}. We 944 then consider a longer interval between doses (i.e. 4 and 8 weeks). Assuming that protection 945 946 against infection starts one week after first-dose inoculation leads to a higher impact of 947 vaccination for all four vaccination strategies.



951 Figure S4. Relative reduction (RR) in the attack rate (AR) after two months for all strategies at equal number of 952 doses. RR is computed with respect to the reference scenario with initial vaccination only. Different parameter 953 values and modelling assumptions are compared. Vaccination rate for mass, workplaces/universities and school 954 location vaccination is set to the average value recovered for reactive vaccination. Exceptions made for the 955 parameter explored in each panel - indicated in the x-axis -, all parameters are as in panel D, E of Figure 2 of the 956 main paper. Parameters explored are: A reproductive ratio; B natural immunity of the population at the start; C 957 repartition of contacts across settings due to social distancing (Intermediate is the baseline scenario, while high is 958 given by a 30% reduction in community contacts and a 20% of individuals doing teleworking); D incubation period, 959 E vaccine-induced reduction in infection duration (yes, no), F vaccine uptake, and G time between doses - the x-960 axis labels wNwM indicates the average number of weeks, N and M, of no protection following first dose 961 inoculation and of intermediate vaccine effectiveness, respectively. Values are means over 2000 stochastic 962 simulations. Error bars are derived from the standard errors of the AR. These are smaller than the size of the dots 963 in almost all cases.

949

The impact of reactive vaccination and its demand in terms of vaccine doses varies 965 966 depending on the incidence level. In Figure S5 A-C we compare all strategies under a 967 scenario of flare-up of cases. We assumed three cases were infected at the beginning. Panels A, B of Figure S5 are the analogous of panel B, E of the Figure 2 of the main paper 968 969 and are obtained with the same parameters exception made for the value of initial incidence -970 notably, we assumed intermediate vaccination coverage at the beginning (\sim 45% of the whole 971 population vaccinated) and the vaccine uptake to be the same for all strategies. Panel A 972 shows the relative reduction in the attack rate after two months as a function of the number of 973 first daily doses, while Panel B compares the incidence profiles under different strategies at 974 equal number of vaccine doses. The relative reduction produced by reactive vaccination is 975 close to the one produced by mass, school location and workplaces/universities. Panel C

- shows the number of vaccines deployed each day for reactive vaccination and the number ofworkplaces/schools where vaccines are deployed. These are initially low and increase
- 978 gradually with incidence.

979 We then explore the impact of the reactive vaccination within the flare-up case in varying the different parameters. Specifically, we compare all strategies at an equal number of doses, 980 varying the level of social distancing (Figure S5 D, analogously to Figure S4 C) and the timing 981 982 for the immunity to mount after the first-dose vaccination (Figure S5 E, analogous to Figure 983 S4 G). For certain parameter values reactive vaccination produces a higher relative reduction in the attack rate compared with non-reactive strategies. This is the case for instance when 984 the development of vaccine immunity is rapid, and when no social restrictions are in place. In 985 986 other cases it produces comparable effect. This is the case for instance of long delays 987 between doses. Finally, in Figure S5 F, we provide an overview of the impact of initial 988 incidence. As initial incidence increases the advantage of the reactive vaccination compared 989 with the non-reactive strategies increases.

990



993 Figure S5. A Relative reduction (RR) in the attack rate (AR) over the first two months for all strategies as a 994 function of the vaccination pace. RR is computed with respect to the reference scenario, with initial vaccination 995 only. AR is computed from clinical cases. B Incidence of clinical cases with different vaccination strategies. The 996 reactive and non-reactive scenarios plotted are obtained with the same average daily number of vaccines, i.e. 55 997 daily first-dose vaccinations per 100,000 inhabitants. C Number of daily first-dose vaccinations, and 998 workplaces/schools (WP/S in the plot) where vaccines are deployed. D AR RR after two months according to the 999 repartition of contacts across settings due to social distancing - Intermediate is the baseline scenario, while high is 1000 given by a 30% reduction in community contacts and a 20% of individuals doing teleworking. E AR RR after two 1001 months according to the timing for the immunity to mount after first-dose vaccination - the x-axis labels wNwM 1002 indicates the average number of weeks, N and M, of no protection following first dose inoculation and of 1003 intermediate vaccine effectiveness, respectively. F AR RR after two months according to the initial incidence for 1004 all strategies at equal number of doses. In panels D-F all strategies are compared at equal number of doses. All 1005 panels, except for panel F, consider a flare up scenario, where the epidemic is seeded with 3 infectious 1006 individuals. All other parameters are as in panels D, E of Figure 2 of the main paper. Values are means over 1007 2000 stochastic simulations. Error bars in panels A, D, E, F are derived from the standard errors of the AR. 1008 Shaded areas in panels B, C, indicate the standard errors.

1009

1010 Additional epidemic outcomes

1011 Based on the estimated incidence of clinical cases per day provided by the transmission

1012 model, we infer outcomes related to hospital, namely hospital and intensive care unit (ICU)

1013 entries, beds in ICU ward, and deaths. We use age-dependent hospital admissions (ICU and

1014 non-ICU) risks estimated by ^{16,17} and ICU admission risks for hospitalised patients based on

1015 SI-VIC extract ¹⁸. Hospital admissions risks were adjusted to apply only to clinical cases ¹⁹ and

1016 to account for vaccine effectiveness for hospitalisation for zero, half (1 dose) and full (2 1017 doses) vaccination. We assumed the vaccine efficacies for hospitalisation were equal to 83% and 94% for half and full vaccinations, respectively⁷. We also assume that the hospital 1018 admission risk increases by 80% with the Delta variant compared to Alpha²⁰ and by 40% with 1019 the Alpha variant compared to the wild type ²¹. Patients who were hospitalised entered the 1020 1021 hospital on average 7 days (sd = 3.9 days – Gamma distribution) after the beginning of the 1022 infectious phase ²². Those who were admitted in ICU enter this unit with a mean delay of 1.69 days (assuming an exponential distribution)¹⁸. To estimate the number of occupied beds, we 1023 1024 use age-specific mean durations of stay and their corresponding standard deviations in ICU 1025 calculated on all the hospitalised cases in the first 9 months of the French epidemic (March-1026 November 2020)¹⁸. We assume that the standard deviations of ICU lengths of stay were equal 1027 to the corresponding mean and do not consider post-ICU care in the estimation of occupied 1028 beds. We estimate the number of deaths using hospital and ICU death risks of hospitalised 1029 infected persons ¹⁸. Deaths are delayed in time using the mean delays and standard deviations from hospital or ICU admission to death ¹⁸. All lengths of stay are supposed to 1030 1031 follow a Gamma distribution. Parameters and their values are summarised in Tables S6 and 1032 S7.

1033 We also estimate the number of life years and quality-adjusted life years (QALY) lost for each
1034 death using life-tables provided by 'French National Institute of Statistics and Economic

- 1035 Studies' (INSEE) for 2012-2016²³ and utility measures of each age-group in France²⁴.
- 1036

Age Group	Hospitalisation risk for no- vaccination	Hospitalisa tion risk for half vaccination	Hospitalisa tion risk for full vaccination	ICU admission risk	Death risk in general ward	Death risk in ICU
		(1 dose)	(2 doses)			
0-9	0.0246	0.0115	0.0066	0.159	0.006	0.078
10-19	0.0136	0.0063	0.0037	0.159	0.006	0.078
20-29	0.0364	0.0170	0.0098	0.159	0.006	0.078
30-39	0.0443	0.0207	0.0119	0.159	0.006	0.078
40-49	0.0617	0.0288	0.0166	0.219	0.016	0.103

1037 Table S6. Risks of hospitalisation according to vaccination status, ICU admission and death in general1038 ward and ICU

70-79 0.5113 0.2386 0.1377 0.235 0.140	0.366
70-79 0.5113 0.2386 0.1377 0.235 0.140	0.366
70-79 0.5113 0.2386 0.1377 0.235 0.140	0.366

Table S7. Delays from hospitalisation admission in general ward to death or hospital discharge and delays
 from ICU admission to ICU discharge or death.

Age	Mean los in general	Mean los in general	Mean los in ICI I	Mean los in ICII for
Group	ward (sd)	ward for dying people (sd)	(sd)	dying people (sd)
0-9	6.4 (6.8)	10.6 (12.3)	12.7 (12.7)	22.3 (22.3)
10-19	6.4 (6.8)	10.6 (12.3)	12.7 (12.7)	22.3 (22.3)
20-29	6.4 (6.8)	10.6 (12.3)	12.7 (12.7)	22.3 (22.3)
30-39	6.4 (6.8)	10.6 (12.3)	12.7 (12.7)	22.3 (22.3)
40-49	6.4 (6.8)	10.6 (12.3)	12.7 (12.7)	22.3 (22.3)
50-59	6.4 (6.8)	10.6 (12.3)	12.7 (12.7)	22.3 (22.3)
60-69	9.3 (9.1)	10.6 (12.3)	16.7 (16.7)	20.8 (20.8)
70-79	11.7 (11.4)	10.6 (12.3)	17.5 (17.5)	18.9 (18.9)
79+	15 (13.8)	10.6 (12.3)	13.6 (13.6)	10.6 (10.6)

1042 Los: Length of stay. Sd = Standard deviation.

1043

Figure S5 shows the relative reductions in the number of hospitalisations, deaths, ICU entries, life-year lost, quality-adjusted life-year lost and ICU bed occupancy at the peak, comparing each vaccination scenario with the reference scenario - i.e. vaccination only at the start. We consider here the high incidence and intermediate vaccine coverage scenario, analogously to Figure 2 D, E of the main paper. The six indicators show a behaviour similar to incidence.

- 1049 Overall reduction values are smaller. This is expected, since a large proportion of elderly are
- 1050 already vaccinated at the start, and the compared vaccination strategies target a population
- 1051 that is less at risk of severe infection. Still all indicators show the same qualitative behaviour,
- 1052 with reactive vaccination outperforming the non-reactive vaccination strategies at equal
- 1053 number of first-dose vaccination.
- 1054



1055

Figure S6. A, B, C, D, E Relative reduction (RR) in the cumulative incidence of hospitalisations, intensive care unit (ICU) entries, deaths, life years (LY) lost and quality-adjusted life years (QALY) lost over the first two months for all strategies as a function of the vaccination pace. F Relative reduction (RR) in occupied ICU beds at the peak over the first two months for all strategies as a function of the average daily number of first-dose vaccinations for the intermediate vaccination coverage scenario. Values are means over 2000 stochastic simulations. Error bars are derived from the standard errors of the AR. Parameters are the same as in Figure 2 D, E of the main paper.

1063 **Combined reactive and mass vaccination for managing sustained**

- 1064 COVID-19 spread:
- 1065 Additional results
- 1066 In Figure S7 we show the incidence curve corresponding to the scenarios analysed in Figure
- 1067 3 A of the main paper. Mass and combined vaccination with the five different vaccination
- 1068 paces are compared.



Figure S7. Incidence of clinical cases for mass and combined vaccination strategies for three different vaccination paces. Scenarios are the same as the ones plotted in Figure 3 A. We assumed the following parameters: initial incidence of clinical cases 160 per 100 000 inhabitants; R=1.6; Initial immunity 32%; vaccinated at the beginning 90% and 40% for 60+ and <60, respectively; 10% of individuals are doing teleworking and 5% of community contacts are removed. Values are means over 2000 stochastic simulations. Shaded areas indicate the standard errors - very low for this set of parameters.

1076

1077

1078 Combined reactive and mass vaccination for managing a COVID-19

- 1079 flare-up
- 1080 Additional results
- 1081 In Figure S8 we show the incidence curve corresponding to the scenarios analysed in Figure
- 1082 4 of the main paper. Mass and combined vaccination with the different vaccination scenarios
- 1083 considered are compared.



1085

Figure S8. Incidence of clinical cases for mass and combined vaccination strategies for the scenarios analysed in
Figure 4 of the main paper. A scenario with enhanced TTI. B scenario with baseline TTI. In all panels we
assumed the following parameters: R=1.6; Initial immunity 32%; 90% for 60+ year old and 40% for <60 years old
already vaccinated at the beginning; 10% of individuals are doing teleworking and 5% of community contacts are
removed. Values are means over 8000 stochastic simulations. Shaded areas indicate the standard errors.

1092 Sensitivity analysis

1093 In Figure S9 we analyse the impact of combined and mass vaccination in a flare up scenario 1094 similarly to Figure 4, by varying the hypotheses on virus transmissibility and vaccine escape. Specifically we consider values of the reproductive ratio from 1.2 to 1.8, and both worst and 1095 1096 baseline vaccine effectiveness level - the worst vaccine effectiveness level is the same as in 1097 Figures 2 I of the main paper. Analogously to Figure 4 we compare the attack rate for 1098 combined and mass vaccination, assuming both baseline and enhanced TTI and both 1099 baseline and 100% vaccine uptake in the context of reactive vaccination. We consider only 1100 the case in which reactive vaccination starts after the detection of the first case. For each set 1101 of parameters, scenarios with enhanced TTI and 100% uptake are associated with smaller 1102 attack rates and larger difference between mass and combined than the corresponding 1103 scenarios with baseline TTI and baseline uptake.



Baseline uptake

• 100% uptake to reactive vacc.

1105

Figure S9. Average attack rate per 100000 inhabitants after two months for the flare up case under different
hypotheses: A, B, R = 1.8 with baseline vaccine effectiveness; C-H worst vaccine effectiveness with R = 1.2 (C,D),
R = 1.6 (E,F) and R = 1.8 (G,H). The worst vaccine effectiveness scenario is defined as in figure 2 I, i.e.

1109 $V E_{s_1} = 30\%, V E_{s_{P_1}} = 35\%, V E_{s_2} = 53\%$ and $V E_{s_{P_2}} = 60\%$. We compare enhanced and baseline

1110 TTI - A, C, E, G and B, D, F, H, respectively -, as well as baseline and 100% vaccine uptake. In all panels,

1111 parameters are the same as in Figure 4: initial immunity 32%; 90% for 60+ year old and 40% for <60 years old

already vaccinated at the beginning; 10% of individuals are doing teleworking and 5% of community contacts are

1113 removed. Values are means over 8000 stochastic realisations. Error bars are the standard error.

1114

We then investigate the impact of combined and mass vaccination on the extinction of the 1115 1116 flare-up. In Figure 10 A we plot the probability of extinction for the scenario considered in 1117 Figure 4 A of the main paper (enhanced TTI and 100% vaccine uptake). We find that the probability of extinction is ~5%, and the difference between mass and combined is ~0.5%. 1118 1119 The probability of extinction progressively increases under more optimistic hypotheses: 1120 increase in case detection from 70% and 30% (enhanced TTI) to 100% and 50% (strong TTI) 1121 for clinical and subclinical cases, respectively; increase in vaccine effectiveness to the best 1122 case scenario considered in Figure 2 I; rapid mounting of the vaccine effect, with partial 1123 immunity against infection already present one week after inoculation. In the best-case 1124 scenario plotted in panel H, the probability of extinction reaches ~ 0.15 and ~ 0.18 for mass 1125 and combined vaccination, respectively.



1128 Figure S10. Probability of extinction for an outbreak of three initial cases for mass vs. combined vaccination,

1129 compared at an equal number of doses. Three sets of parameters are investigated. 1) Baseline vaccine

1130 effectiveness (A,B,E,F) vs best effectiveness, i.e. $V E_{S,1} = 65\%$, $V E_{SP,1} = 75\%$, $V E_{S,2} = 80\%$ and

1131 $V E_{SP,2} = 95\%$, (C,D,G,H); 2) enhanced TTI (A,C,E,G) vs. strong TTI with $p_{d,c}$ = 1 and $p_{d,sc}$ = 0.5 (B,D,F,H). 3)

1132 2 weeks (baseline) for vaccines to reach partial effectiveness (A,B,C,D) vs 1 week (E,F,G,H). In all panels,

- parameters are the same as in Figure 4: initial immunity 32%; 90% for 60+ year old and 40% for <60 years old
- already vaccinated at the beginning; 10% of individuals are doing teleworking and 5% of community contacts are

1135 removed. Values are means over 15000 stochastic realisations. Error bars are the standard error.

1136

1137 **References**

- 1138 1. López, J. A. M. et al. Anatomy of digital contact tracing: role of age, transmission setting,
- 1139 adoption and case detection. *medRxiv* 2020.07.22.20158352 (2020)
- 1140 doi:10.1101/2020.07.22.20158352.
- 1141 2. Kang, M. et al. Transmission dynamics and epidemiological characteristics of Delta variant
- 1142 *infections in China*. 2021.08.12.21261991
- 1143 https://www.medrxiv.org/content/10.1101/2021.08.12.21261991v1 (2021)
- doi:10.1101/2021.08.12.21261991.
- 1145 3. Lauer, S. A. et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From
- 1146 Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 172,
- 1147 577–582 (2020).
- 1148 4. Xin, H. et al. The Incubation Period Distribution of Coronavirus Disease 2019: A

1149 Systematic Review and Meta-analysis. *Clinical Infectious Diseases* (2021) doi:10.1093/cid/

1150 ciab501.

- 1151 5. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature*1152 *Medicine* 1–4 (2020) doi:10.1038/s41591-020-0869-5.
- 1153 6. Di Domenico, L., Pullano, G., Sabbatini, C. E., Boëlle, P.-Y. & Colizza, V. Impact of
- 1154 lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. BMC
- 1155 *Medicine* **18**, 240 (2020).
- 1156 7. Higdon, M. M. et al. A systematic review of COVID-19 vaccine efficacy and effectiveness
- against SARS-CoV-2 infection and disease. 2021.09.17.21263549
- 1158 https://www.medrxiv.org/content/10.1101/2021.09.17.21263549v1 (2021)
- doi:10.1101/2021.09.17.21263549.
- 1160 8. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New
- 1161 *England Journal of Medicine* **383**, 2603–2615 (2020).
- 1162 9. Kissler, S. M. et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and
- 1163 *unvaccinated individuals*. 2021.02.16.21251535
- 1164 https://www.medrxiv.org/content/10.1101/2021.02.16.21251535v3 (2021)
- 1165 doi:10.1101/2021.02.16.21251535.
- 1166 10. SPF. COVID-19 : point épidémiologique du 6 mai 2021.
- 1167 https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-
- 1168 respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-
- 1169 epidemiologique-du-6-mai-2021.
- 1170 11. Smith, L. E. *et al.* Adherence to the test, trace and isolate system: results from a time
- 1171 series of 21 nationally representative surveys in the UK (the COVID-19 Rapid Survey of
- 1172 Adherence to Interventions and Responses [CORSAIR] study). *medRxiv* (2020)
- 1173 doi:10.1101/2020.09.15.20191957.
- 1174 12. Info Coronavirus COVID-19 Tester Alerter Protéger. Gouvernement.fr
- 1175 https://www.gouvernement.fr/info-coronavirus/tests-et-depistage.
- 1176 13. CoviPrev : une enquête pour suivre l'évolution des comportements et de la santé
- 1177 mentale pendant l'épidémie de COVID-19. https://www.santepubliquefrance.fr/etudes-et-

- 1178 enquetes/coviprev-une-enquête-pour-suivre-l'évolution-des-comportements-et-de-la-
- 1179 sante-mentale-pendant-l-epidemie-de-covid-19.
- 1180 14. Nasreen, S. et al. Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against
- 1181 symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in
- 1182 Ontario. 2021.06.28.21259420
- 1183 https://www.medrxiv.org/content/10.1101/2021.06.28.21259420v3 (2021)
- 1184 doi:10.1101/2021.06.28.21259420.
- 1185 15. Tang, P. et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against
- 1186 the SARS-CoV-2 Delta variant in Qatar. *Nat Med* 1–8 (2021) doi:10.1038/s41591-021-
- 1187 01583-4.
- 1188 16. Kiem, C. T. *et al.* Short and medium-term challenges for COVID-19 vaccination: from 1189 prioritisation to the relaxation of measures. (2021).
- 1190 17. Lapidus, N. et al. Do not neglect SARS-CoV-2 hospitalization and fatality risks in the
- 1191 middle-aged adult population. *Infectious Diseases Now* **51**, 380–382 (2021).
- 1192 18. Lefrancq, N. et al. Evolution of outcomes for patients hospitalised during the first 9
- 1193 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data

analysis. *The Lancet Regional Health – Europe* **5**, (2021).

- 1195 19. Davies, N. G. et al. Age-dependent effects in the transmission and control of COVID-
- 1196 19 epidemics. *Nature Medicine* 1–7 (2020) doi:10.1038/s41591-020-0962-9.
- 1197 20. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in
- Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* **397**, 2461–2462 (2021).
- 1200 21. Bager, P. and Wohlfahrt, J. and Rasmussen, M. and Albertsen, M and Grove Krause,
- T. Hospitalisation associated with SARS-CoV-2 delta variant in Denmark. *Lancet Infect Dis*(2021).
- 1203 22. Salje, H. *et al.* Estimating the burden of SARS-CoV-2 in France. *Science* (2020)
 1204 doi:10.1126/science.abc3517.
- 1205 23. Tables de mortalité par sexe, âge et niveau de vie Tables de mortalité par niveau
- de vie | Insee. https://www.insee.fr/fr/statistiques/3311422?sommaire=3311425.

- 1207 24. Chevalier, J. & de Pouvourville, G. Valuing EQ-5D using time trade-off in France. *Eur*
- *J Health Econ* **14**, 57–66 (2013).